Sabizabulin - Veru Healthcare
Alternative Names: APP-111; Bisindole; VERU-111Latest Information Update: 09 Aug 2024
At a glance
- Originator Ohio State University; University of Tennessee Research Foundation
- Developer University of Tennessee Research Foundation; Veru Healthcare
- Class Anti-inflammatories; Antineoplastics; Antivirals; Imidazoles; Indoles; Ketones; Phenyl ethers; Small molecules
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Ebola virus infections; Smallpox
- Preclinical HER2 positive breast cancer
- Suspended COVID 2019 infections; Influenza A virus H1N1 subtype; SARS-CoV-2 acute respiratory disease
- No development reported Solid tumours
- Discontinued Prostate cancer
Most Recent Events
- 09 Aug 2024 Discontinued - Phase-III for Prostate cancer (Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 07 Aug 2024 Suspended - Phase-II for SARS-COV-2 acute respiratory disease in USA (PO)
- 07 Aug 2024 Suspended - Phase-III for COVID-2019 infections in Argentina (PO)